Shoman Kasbekar

Shoman Kasbekar is a Principal at Foresite Capital, where he serves on TechAtlas, the firm's internal research and diligence team. He originally joined the firm as an associate seeking broad exposure to evaluate investment opportunities across the biotechnology sector, ranging from early-stage company formation to commercial-stage public equities. Operating across functions that mirror venture capital, hedge fund, and consulting methodologies, Kasbekar has directed capital into multiple emerging therapeutic modalities. He notably acted as the lead partner alongside CEO Nenad Tomasevic for Dren Bio's Series A financing. In February 2024, he supported principal Mitra Miri in executing a $170 million Series D funding round for BioAge, while also managing strategic investments in Crossbow Therapeutics. His current investment focus centers on advancing cell therapies and novel therapeutic modalities across all stages of clinical and commercial development.